Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter randomized study is to compare efficacy and safety of
dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic
phase (CP) chronic myeloid leukemia (CML)